Delivra Health Brands (TSE:DHB)
:DHB
Top Page
Delivra Health Brands
(DHB)
Select Model
Select Model
Rating:43Neutral
Price Target:
C$0.15
▲(2.67% Upside)
Action:ReiteratedDate:03/19/26
The score is primarily held back by continued losses and inconsistent/negative cash flow, despite improved gross profitability and manageable leverage. Technical indicators also point to a continuing downtrend, and valuation is constrained by a negative P/E with no dividend support.
Positive Factors
Margin sustainability
Healthy gross margins near 50% provide a durable profitability buffer for a consumer products company. Sustained mid‑range gross margin supports operating leverage as sales scale, improving the odds of moving to positive operating profit without relying solely on price hikes.
Negative Factors
Ongoing unprofitability
TTM net margin near -6% and slightly negative EBIT show the turnaround is incomplete. Continued losses erode retained capital, restrict reinvestment, and increase reliance on external financing, raising dilution and execution risk if structural profitability isn't achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Margin sustainability
Healthy gross margins near 50% provide a durable profitability buffer for a consumer products company. Sustained mid‑range gross margin supports operating leverage as sales scale, improving the odds of moving to positive operating profit without relying solely on price hikes.
Read all positive factors
Delivra Health Brands (DHB) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$4.69M
Dividend YieldN/A
Average Volume (3M)26.13K
Price to Earnings (P/E)―
Beta (1Y)1.85
Revenue Growth13.01%
EPS Growth-2445.45%
CountryCA
Employees22
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding31,261,782
10 Day Avg. Volume58,945
30 Day Avg. Volume26,134
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.30
Price to Sales (P/S)0.41
P/FCF Ratio-7.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.60Price Target Upside300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)C$14.97M
Delivra Health Brands Business Overview & Revenue Model
Company Description
Delivra Health Brands Inc. through its subsidiaries, provides lifestyle and wellness products to consumers and patients in regulated markets worldwide. The company is involved in selling of cannabis, liquid sleep shots, sleep powder packets, gummi...
How the Company Makes Money
null...
Delivra Health Brands Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
56
Neutral
Cash Flow
33
Negative
| Breakdown | TTM | Sep 2025 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.09M | 13.37M | 12.38M | 9.79M | 8.14M | 7.96M |
| Gross Profit | 6.36M | 6.78M | 6.40M | 3.49M | 485.00K | -297.00K |
| EBITDA | 307.00K | 427.00K | 2.35M | 1.40M | -4.25M | -7.04M |
| Net Income | -405.00K | -1.19M | 876.00K | -184.00K | -7.01M | -28.54M |
Balance Sheet | ||||||
| Total Assets | 8.04M | 9.61M | 10.05M | 10.56M | 11.59M | 19.06M |
| Cash, Cash Equivalents and Short-Term Investments | 3.23M | 3.30M | 4.20M | 2.73M | 1.11M | 5.14M |
| Total Debt | 2.26M | 2.11M | 2.03M | 1.96M | 2.11M | 2.16M |
| Total Liabilities | 4.25M | 5.37M | 4.86M | 7.17M | 8.21M | 9.09M |
| Stockholders Equity | 3.80M | 4.24M | 5.19M | 3.39M | 3.37M | 9.98M |
Cash Flow | ||||||
| Free Cash Flow | -111.00K | -754.00K | 756.00K | -1.13M | -4.46M | -9.68M |
| Operating Cash Flow | -111.00K | -754.00K | 756.00K | -1.09M | -4.44M | -9.65M |
| Investing Cash Flow | 0.00 | 0.00 | 11.00K | 2.91M | 1.35M | 12.27M |
| Financing Cash Flow | -20.00K | -36.00K | 594.00K | -255.00K | -309.00K | 446.00K |
Delivra Health Brands Technical Analysis
Negative
0.15
Price Trends
0.17
Negative
0.20
Negative
0.22
Negative
Market Momentum
>-0.01
Negative
46.09
Neutral
77.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DHB, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.17, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.09 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DHB.
Delivra Health Brands Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | C$4.96M | -3.46 | ― | ― | -2.30% | ― | |
45 Neutral | C$6.92M | 5.19 | ― | ― | 15.64% | 58.47% | |
43 Neutral | C$4.69M | -3.90 | -9.77% | ― | 13.01% | -2445.45% | |
43 Neutral | C$3.84M | -6.37 | 50.26% | ― | 1.60% | -213.10% |
* General Sector Average
TSE:DHB
Delivra Health Brands
0.15
-0.02
-11.76%
TSE:TGIF
1933 Industries
0.01
0.00
0.00%
TSE:PCLO
PharmaCielo
0.05
-0.04
-43.75%
TSE:SPR
Sproutly Canada
0.02
0.00
0.00%
TSE:CDVA
CordovaCann
0.04
-0.08
-69.57%
Delivra Health Brands Corporate Events
Business Operations and StrategyProduct-Related Announcements
Delivra Health Unveils Dream Water Kids Sleep Gummies and Grants New Stock Options
Positive
Mar 19, 2026
Delivra Health Brands is expanding its Dream Water portfolio with the launch of Dream Water Kids Sleep Gummies in the U.S. market, expected to reach distributors, retailers, and online channels in June 2026. The kid-focused gummies, formulated wit...
Business Operations and StrategyFinancial Disclosures
Delivra Health Q2 Revenue Slips as E-Commerce Growth Offsets Retail Weakness
Negative
Feb 28, 2026
Delivra Health reported weaker second-quarter fiscal 2026 results as net revenue fell 12% to $2.4 million, driven by lower Dream Water sales in the U.S. and Canada, reduced LivRelief retail and infused cream volumes, and a shift in distribution ch...
Business Operations and StrategyExecutive/Board Changes
Delivra Health Brands Adds Veteran CPG Executive John Barrett to Board
Positive
Jan 30, 2026
Delivra Health Brands has appointed John Barrett, a veteran consumer goods executive with senior leadership experience at Frito Lay, PepsiCo and Pernod Ricard, to its board of directors, replacing outgoing director Andrew Bayfield. Currently head ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.